<p>In HIV prevention and treatment, broadly neutralising antibodies have so far failed failed to deliver on their potential; could N6LS buck the trend? Richard Wu talks about a phase 1 study with some promising results.</p>

In HIV prevention and treatment, broadly neutralising antibodies have so far failed failed to deliver on their potential; could N6LS buck the trend? Richard Wu talks about a phase 1 study with some promising results.

In conversation with... Richard Wu

The Lancet HIV launched in autumn 2014, joining the growing collection of Lancet specialty journals. As an exclusively online journal, this new monthly title delivers a holistic view of the pandemic, publishing original research, comment, and correspondence that unifies clinical, epidemiological, and operational disciplines across a single vision of health for those living with HIV.

Share In conversation with... Richard Wu

Sign up to save your podcasts

In conversation with... Richard Wu

In conversation with... Richard Wu